Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.5K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.8K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.8K
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

438
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
438
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

553
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
553

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renal Cell Carcinoma of Native Kidneys in Kidney Allograft Recipients: Are There Any Guidelines for Management?

Journal of clinical medicine·2026
Same author

Diagnosis of Sporadic Creutzfeldt-Jakob Disease in Both Kidney Recipients From the Same Donor: Was It Graft Transmission?

Cureus·2026
Same author

Hypothermic Machine Perfusion Allows Safe Delay in Kidney Transplantation After Cold Storage.

Journal of clinical medicine·2026
Same author

Cardiogenic shock treated effectively by Berlin Heart implantation in a young patient with systemic lupus erythematosus.

Kardiologia polska·2026
Same author

Sustained low-efficiency dialysis-an old method but possibly a new solution for environmental nephrology.

Renal failure·2025
Same author

Sex-related disparities in cognitive impairment in kidney transplant patients with kidney failure.

Journal of nephrology·2025

Related Experiment Video

Updated: Mar 9, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.6K

[Hyperkalemia - current therapuetic strategies].

Tomasz Głogowski1, Ewa Wojtaszek2

  • 1Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska, tomglogowski@gmail.com.

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|December 30, 2016
PubMed
Summary

Hyperkalemia, a serious condition often seen in chronic kidney disease patients, requires immediate treatment and prevention strategies. New medications offer a shift towards proactive management, preventing dangerous potassium level fluctuations.

Keywords:
cation exchange resinschronic kidney diseasepatiromerzirconium cyclosilicatehyperkalemia

More Related Videos

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.7K
Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
11:20

Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain

Published on: May 7, 2018

12.8K

Related Experiment Videos

Last Updated: Mar 9, 2026

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.6K
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.7K
Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
11:20

Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain

Published on: May 7, 2018

12.8K

Area of Science:

  • Nephrology
  • Internal Medicine
  • Pharmacology

Background:

  • Hyperkalemia is a critical medical condition necessitating urgent treatment and long-term management strategies.
  • Patients with chronic kidney disease (CKD) are particularly susceptible to hyperkalemia due to impaired kidney function and common comorbidities like diabetes and heart failure.
  • Medications, especially renin-angiotensin-aldosterone system inhibitors (RAASi), frequently contribute to hyperkalemia in these patients.

Purpose of the Study:

  • To highlight the challenges in managing hyperkalemia, particularly in patients with CKD.
  • To discuss the limitations of current therapeutic approaches for restoring potassium homeostasis.
  • To introduce the potential of novel medications in shifting hyperkalemia management towards preventive strategies.

Main Methods:

  • Review of current medical literature on hyperkalemia management.
  • Analysis of the role of comorbidities and medications in hyperkalemia development.
  • Evaluation of the therapeutic potential of new agents like patiromer and ZS-9.

Main Results:

  • Current management often focuses on treating triggers rather than providing continuous potassium regulation.
  • New medications, patiromer and ZS-9, show promise in stabilizing serum potassium levels.
  • These new agents may enable the continued use of essential RAASi therapy by mitigating hyperkalemia risk.

Conclusions:

  • Effective management of hyperkalemia requires both immediate intervention and strategies to prevent recurrence.
  • Novel potassium binders represent a significant advancement, potentially transforming hyperkalemia treatment from reactive to proactive.
  • Preventive measures using new medications can improve patient outcomes by allowing the use of life-sustaining therapies that might otherwise induce hyperkalemia.